Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 4/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.42 |
| ▸ | SMYD2 | Q9NRG4 | 6/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.38 |
| ▸ | ITK | Q08881 | 1/20 | 0.38 |
| ▸ | SLC34A2 | O95436 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | AURKA | O14965 | 1/20 | 0.36 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL40118 | 0.91 | CHRM3 (0.43) | KDM1AHDAC1SMYD2CXCR3SLC34A2 | |
| SCHEMBL40112 | 0.87 | SLC34A2 (0.48) | KDM1AHDAC1SMYD2KDM4ESLC34A2 | |
| SCHEMBL39969 | 0.84 | SLC34A2 (0.45) | KDM1AHDAC1SMYD2MAPTKDM4E | |
| SCHEMBL46466 | 0.84 | SLC34A2 (0.41) | SMYD2KDM4ESLC34A2ROCK2 | |
| SCHEMBL39823 | 0.84 | SLC34A2 (0.46) | KDM1AHDAC1KDM4ESLC34A2 | |
| SCHEMBL40739 | 0.83 | SLC34A2 (0.46) | SMYD2NPSR1SLC34A2ROCK2 | |
| SCHEMBL46529 | 0.83 | SLC34A2 (0.46) | KDM1AHDAC1SMYD2KDM4ESLC34A2 | |
| SCHEMBL15432568 | 0.83 | SLC34A2 (0.45) | KDM1AHDAC1SMYD2KDM4ESLC34A2 | |
| SCHEMBL46679 | 0.83 | SLC34A2 (0.47) | SMYD2KDM4ESLC34A2ROCK2 | |
| SCHEMBL18482714 | 0.83 | SLC34A2 (0.44) | KDM1AHDAC1SMYD2KDM4ESLC34A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2590656-B1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX INC (US) | 2017-11-15 | — | — | EP | disclosed |
| US-20170037010-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. | 2017-02-09 | — | — | US | disclosed |
| US-20170037010-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. | 2017-02-09 | — | — | US | disclosed |
| EP-2591354-B1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX INC (US) | 2016-09-07 | — | — | EP | disclosed |
| US-9301951-B2 | Compounds and methods for inhibiting phosphate transport | ARDELYX, INC. (US) | 2016-04-05 | — | — | US | disclosed |
| US-9301951-B2 | Compounds and methods for inhibiting phosphate transport | ARDELYX, INC. (US) | 2016-04-05 | — | — | US | disclosed |
| US-20150164876-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. | 2015-06-18 | — | — | US | disclosed |
| US-20150164876-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. | 2015-06-18 | — | — | US | disclosed |
| US-8916569-B2 | Compounds and methods for inhibiting phosphate transport | ARDELYX, INC. (US) | 2014-12-23 | — | — | US | disclosed |
| US-8916569-B2 | Compounds and methods for inhibiting phosphate transport | ARDELYX, INC. (US) | 2014-12-23 | — | — | US | disclosed |
| US-20140023611-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. | 2014-01-23 | — | — | US | disclosed |
| US-20140023611-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. | 2014-01-23 | — | — | US | disclosed |
| WO-2012006475-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. (US) | 2012-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150164876-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | SLC34A2, SLC34A1, SLC10A2 | KDM1A 4426/4885HDAC1 2715/4885SMYD2 4600/4885 |
| US-20170037010-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | SLC34A2, SLC34A1, SLC10A2 | KDM1A 4426/4885HDAC1 2715/4885SMYD2 4600/4885 |
| US-20140023611-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | SLC10A2, SLC34A2, SLC34A3 | KDM1A 4841/4885HDAC1 3309/4885SMYD2 4638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.